As of Wednesday close, RVL Pharmaceuticals plc’s (NASDAQ:RVLP) stock traded at $0.12. The average number of shares traded per day over the past five days has been 3,348,020 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.0024 fall in that time frame. In the last twenty days, the average volume was 6,140,665, while in the previous 50 days, it was 2,720,512.
Since last month, RVLP stock retreated -26.65%. Shares of the company fell to $0.0929 on 08/30/23, the lowest level in the past month. A 52-week high of $2.85 was reached on 03/20/23 after having rallying from a 52-week low of $0.09. Since the beginning of this year, RVLP’s stock price has dropped by -89.55% or -$1.0030, and marked a new high 14 times. However, the stock has declined by -95.89% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
The stock’s beta is 1.03. Besides these, the trailing price-to-sales (P/S) ratio of 0.35, the price-to-book (PB) ratio of 0.73.
Financial Health
In the three months ended June 29, RVL Pharmaceuticals plc’s quick ratio stood at 0.40, while its current ratio was 0.40, showing that the company is not able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 74.70% percent. Based on annual data, RVLP earned $40.27 million in gross profit and brought in $49.72 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -54.60%. Return on equity (ROE) for the past 12 months was -155.20%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. RVLP’s revenue fell -15.6% to $8.83 million during the quarter, while net income inched up to $7.31 million. While analysts expected RVL Pharmaceuticals plc to report -$0.11 quarterly earnings, the actual figure was -$0.24 per share, beating the consensus estimate by -118.20%. During the quarter, the company generated -$8.03 million in EBITDA. The liabilities of RVL Pharmaceuticals plc were 69.08 million at the end of its most recent quarter ended June 29, and its total debt was $58.15 million. The value of shareholders’ equity is $99.53 million.
Technical Picture
This quick technical analysis looks at RVL Pharmaceuticals plc’s (RVLP) price momentum. With a historical volatility rate of 57.54%, the RSI 9-day stood at 36.44% on 20 September.
With respect to its five-day moving average, the current RVL Pharmaceuticals plc price is down by -2.01% percent or -$0.0024. At present, RVLP shares trade -16.67% below its 20-day simple moving average and -86.08% percent below its 100-day simple moving average. However, the stock is currently trading approximately -76.13% below its SMA50 and -92.40% below its SMA200.
Stochastic coefficient K was 34.22% and Stochastic coefficient D was 37.04%, while ATR was 0.0216. Given the Stochastic reading of 31.02% for the 14-day period, the RSI (14) reading has been calculated as 32.66%.
Analyst Ratings
RVL Pharmaceuticals plc (RVLP) has been rated Buy by analysts. According to 0 brokerage firms, RVLP is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 1 analyst rate RVL Pharmaceuticals plc stock as buy, with 2 recommending it as overweight.
With a median target price of $2.50, the current consensus forecast for the stock is $1.60 – $6.00. Based on these forecasts, analysts predict RVL Pharmaceuticals plc (RVLP) will achieve an average price target of $3.15.
